Belzutifan for Advanced Pheochromocytoma or Paraganglioma

Le résumé fourni par la source

To the Editor: Jimenez et al. (Nov. 20 issue) 1 report that the hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan resulted in an objective response in 26% of participants and disease control in 85% of participants with advanced pheochromocytoma or paraganglioma, with a median progression-free survival of 22.3 months. Prospective data on peptide receptor radionuclide therapy are encouraging. In the series by Severi et al. involving 46 patients with metastatic somatostatin receptor–positive pheochromocytoma or paraganglioma, treatment with 90 Y-DOTATOC or 177 Lu-DOTATATE resulted in disease control in 80% and prolonged progression-free survival and overall survival, with limited renal and bone marrow toxic effects. 2 Similarly, . . .

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.